fullerene c60 has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balin, K; Dulski, M; Głowacka, O; Korzuch, J; Madeja, Z; Musioł, R; Rak, M; Serda, M; Zubko, M | 1 |
| Brown, AP; Chung, EJ; Citrin, DE; Mitchell, JB; Shankavaram, UT; Shield, WP; Sowers, AL; Thetford, A; Urick, ME | 1 |
2 other study(ies) available for fullerene c60 and Prostatic Neoplasms
| Article | Year |
|---|---|
Towards water-soluble [60]fullerenes for the delivery of siRNA in a prostate cancer model.
Topics: Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; Fullerenes; Humans; Lipids; Male; Nanostructures; Prostatic Neoplasms; RNA, Small Interfering; Solubility | 2021 |
Evaluation of the fullerene compound DF-1 as a radiation protector.
Topics: Adenocarcinoma; Animals; Bone Marrow; Cells, Cultured; Fibroblasts; Fullerenes; Humans; Hypoxia; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Pancreatic Neoplasms; Prostatic Neoplasms; Radiation Injuries; Radiation-Protective Agents; Whole-Body Irradiation | 2010 |